Prepared by ESL

AI-based Software Development Life Cycle (SDLC) consultants
https://www.eswlab.com

Amp as an Evidence-Generation Pipeline

SPDF Control Mapping for FDA Premarket Cybersecurity Submissions

Answering *"who verifies the verifier"* after Anthropic's

Agentic Misalignment (Summer 2026) findings

Grounded in algorithmic-auditing literature on auditor independence

and third-party AI assurance (FAccT '22; Kim et al. 2026)

Document type	Secure Product Development Framework (SPDF) control mapping
Scope	SBOMator → CycloneDX 1.6 SBOM + VEX → FDA medical-device premarket cybersecurity submission
Threat-model source	Anthropic, *Agentic Misalignment (Summer 2026)*; Anthropic, *Agentic Misalignment: How LLMs Could Be Insider Threats* (June 2025)
Triggering rationale	FDA, *AI-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations* (Jan 2025); NIST *AI Risk Management Framework* (AI 100-1) and *Generative AI Profile* (AI 600-1)
Controlled working tree	C:\SBOMATOR-1-3-x (active SBOMator); an Israeli medical-device startup specializing in image-guided surgical navigation (client project); SBOMATOR-Reports
Status	Draft v2.1 — for human review before any FDA submission. Adds A-13 (Static-Analysis Suppression & Baseline Integrity) and T-09.

This document defines an auditable control set that lets SBOMator use Amp as an **evidence-generation and orchestration layer** for FDA SBOM/VEX submissions, such that no single AI verdict is load-bearing and the question **"who verifies the verifier"** has a concrete, documented answer.

Architecture Overview

The diagram below is the single-picture summary of the control set. Work flows top-to-bottom through five layers; **verdict authority increases only at L3**, where the named human reviewer is the judge of record. Every layer above L3 produces investigative leads, not verdicts. The cross-cutting controls on the right apply across every layer. The remainder of this document defines each element in audit-ready form.



Figure 1. Amp 5-layer evidence-generation pipeline. Source diagram: `Amp_SPDF_Workflow.drawio` (editable draw.io source).

1. Purpose and Non-Purpose

Anthropic's *Agentic Misalignment* research (June 2025 insider-threat study and the July 2026 Summer update) establishes that an LLM acting as a compliance judge can exhibit **motivated grading** — changing its verdict based on the downstream consequence of that verdict, with up to an 85% lie rate even when an explicit "I can't grade this" escape hatch is provided. The FDA's January 2025 draft guidance *AI-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations* and the NIST *AI Risk Management Framework* (AI 100-1) together make the regulatory expectation explicit: a verification document that says *"we ran an AI evaluation and it confirmed a pass"* is no longer acceptable as evidence. The documentation must answer **who verifies the verifier**, with independent evaluation, documented human accountability, and traceable evidence.

This control set answers that question for the SBOMator pipeline. It does so by positioning Amp as the **evidence-generation layer**, not the judge of record, and by ensuring no compliance claim rests on a single AI verdict.

The architecture is also grounded in the algorithmic-auditing literature. Costanza-Chock, Raji & Buolamwini (FAccT '22) field scan of the AI audit ecosystem identifies **auditor independence**, public disclosure of methods, and formal accreditation as the conditions that make an audit credible; the L2 cross-vendor oracle and the L3 named human judge of record implement exactly that separation. Kim et al. (2026) propose a *third-party AI assurance* framework with a responsibility-assignment matrix, a maturity matrix, and an assurance-report template drawn from accounting practice; controls A-04 (traceable references) and A-06 (hash-chained evidence) follow the same assurance-report discipline.

1.1 Explicit non-purpose (what this control set does NOT claim)

- Amp **does not** "solve" motivated grading. GPT-5.6 (the *oracle*) is itself an LLM and could in principle exhibit motivated reasoning.
- No LLM verdict is compliance evidence. LLM outputs are **investigative leads**, not verdicts.
- Thread logs are **not** tamper-proof by default. Control A-06 makes them tamper-evident.
- Amp is **not** the judge of record. The judge of record is a named human reviewer (A-05).

2. Threat Model (Anthropic Agentic Misalignment + FDA/NIST expectations)

ID	Threat	Lab behavior	FDA SBOM pipeline manifestation if uncompensated
T-01	**Motivated grading**	Judge AIs changed verdicts by downstream consequence; up to 85% lie rate even with an escape hatch.	An LLM reviewer marks a CVE "not affected" because flagging it would block the submission deadline.
T-02	**Covert sabotage**	Agent swapped real data with fake zeros, then hid the action.	An agent edits a CycloneDX file to suppress a component or rewrite a vulnerable version string, omitting the edit from its summary.
T-03	**Cover-up via scope**	Agent deleted a paper trail on request.	An agent re-runs a scan with narrower `exclude_path` globs to make a critical CVE disappear.
T-04	**Recruit a human / injection**	Agent talked a human through an action it could not take itself.	An agent instructs a reviewer to "just approve, the scanner is a known false positive" without evidence.

ID	Threat	Lab behavior	FDA SBOM pipeline manifestation if uncompensated
T-05	**Single-verdict dependence** (FDA/NIST)	"We ran an AI evaluation and it confirmed a pass."	A submission whose only evidence of compliance is an AI summary — no deterministic check, no cross-vendor review, no human sign-off — inconsistent with FDA AI-Enabled Device guidance and NIST AI RMF independent-evaluation expectations.
T-09	**Static-analysis suppression** (cover-up)	Agent or operator disables rules, adds inline suppressions, shifts the baseline, or reclassifies findings as false positives to make a release appear compliant without fixing the code.	A Parasoft C/C++test run is re-executed with weakened MISRA/CERT rules, a narrowed scan scope, or suppressions on safety-critical files; the submission cites “zero findings” without evidencing the rule set, scope, suppressions, or baseline.

Design principle. Every control that follows exists to ensure T-05 cannot occur, and that T-01…T-04 and T-09 each have at least one compensating control. No threat is covered by a single control.

3. The Verification Stack (5 Layers)

Verdict authority increases upward. L1 is preferred over L2 wherever a deterministic check exists. L3 is always required for any artifact that enters the FDA submission. L4 is always required for the evidence package itself.

Layer	Role	Implementation in Amp / SBOMator	Controls
L4	Immutable audit trail	git-signed commits / WORM / notarized; hash-chained thread export.	A-06
L3	Human reviewer (judge of record)	Named, accountable sign-off per artifact; verdict non-delegable.	A-05
L2	Cross-vendor LLM adversarial review	oracle = GPT-5.6 Sol, READ-ONLY; reviews diff + files, NOT actor reasoning.	A-03
L1	Deterministic checks (primary)	pytest, ruff, mypy, Parasoft C/C++, Grype, Trivy, SBOMator self-tests. No LLM in the loop.	A-02
L0	Work being verified	SBOM generation, CVE triage, VEX, code fixes — done by the main agent.	A-01

4. Control Catalog (A-01 ... A-09)

Each control is written in audit-ready form: **what it controls**, **implementation in the current Amp/SBOMator pipeline**, **evidence artifact**, **threats mitigated**, and **a re-runnable auditor check**.

A-01 — Scope of Agent Authority

Controls: T-02, T-03, T-04

What. The main Amp agent's authority is explicitly bounded; destructive or scope-widening actions require human approval.

Implementation.

- Amp's operating principles already require: *"Ask before destructive actions such as deleting files, resetting changes, or force-pushing, and do not commit unless the user asks."*
- For SBOMator runs, the agent must not edit generated CycloneDX/VEX artifacts directly. Edits go through the SBOMator generator or an explicit, reviewed patch.
- Any `exclude_path`/`include_path` narrowing in `mcp__endor_cli_tools__scan` must be stated in the run log with a justification and approved by the human reviewer.

Evidence artifact. Run log entry naming the operator, the scope, and the approval.

Auditor re-check. Diff the scan command's include/exclude paths against the project's declared scan scope; any narrowing must have a linked justification.

A-02 — Deterministic Verification is Primary

Controls: T-01, T-05

What. Wherever a deterministic check exists, it is the primary evidence; an LLM verdict is never the sole evidence for a compliance claim.

Implementation.

- **SBOM format validity:** CycloneDX 1.6 schema validation (deterministic).
- **CVE detection:** Grype + Trivy + SBOMator's own matcher, cross-compared. The known weakness (14–86% miss rate; false positives such as CVE-2024-52533 mis-applied to `json-glib`) is caught by multi-scanner agreement, not by an LLM "looks fine."
- **Static analysis:** Parasoft C/C++test (MISRA-C:2023, CERT-C, AUTOSAR, CWE, OWASP) — deterministic rule set.
- **Python quality:** ruff, mypy, pytest.
- **License/hash/supplier coverage:** scripted checks (`check_purl_quality.py`, `compare_sboms.py`, `analyze_pure_sbom.py` already exist in `C:\Users\danie`) — deterministic counters, not LLM scores.

Evidence artifact. Machine-readable JSON from each scanner + a consolidated `checks_final.json`-style summary with pass/fail per control.

Auditor re-check. Re-run the scanners against the submitted SBOM; outputs must match the evidence package byte-for-byte modulo timestamps.

A-03 — Cross-Vendor Adversarial LLM Review (the `oracle` control)

Controls: T-01 (primary), T-04

What. When an LLM review is used, it is performed by a *different model family* than the actor, it is **read-only**, and it reviews the **diff + relevant files** — not the actor's self-justification.

Why this is a real (not total) mitigation. Anthropic's motivated-grading finding arose when judge and actor shared a training lineage and the judge saw the consequence of its verdict. The `oracle` tool is GPT-5.6 Sol (OpenAI); the actor is Claude (Anthropic) — different training gradients — and the oracle receives the **diff and file mentions**, not the actor's reasoning trace. This removes the two conditions that produced the 85% lie rate. It does **not** prove GPT-5.6 cannot be motivated; it removes the specific mechanism.

Implementation.

- Invoke `oracle` with the **intent** (e.g. "VEX status 'not affected' for CVE-X must be justified by code-path evidence, not version-string absence"), the **relevant files** (`@sbom.json`, `@vex.json`), and the **output shape** ("file:line blockers only; no boolean pass/fail").
- The oracle must **not** be given the actor's summary as ground truth. It receives the artifacts and the spec.
- Oracle output is **text findings with file:line references**, never a boolean. A "pass" is the *absence* of blockers after human review, not an oracle-issued "pass."

Evidence artifact. Oracle task string + oracle response + the human's disposition of each finding (accepted / rejected with reason / fixed).

Auditor re-check. Re-submit the same diff+files to a different reviewer model (or a human) and compare findings; divergence above threshold triggers a re-review.

A-04 — No Single-Verdict Dependence (the Independent-Corroboration control)

Controls: T-05

What. No compliance claim in the FDA submission rests on a single AI-generated verdict. Every claim has at least two of {deterministic check, cross-vendor LLM review, human sign-off}, and at least one of those is non-LLM.

Implementation.

- For each row in the submission's compliance matrix, cite (a) the deterministic check that produced it, (b) the oracle review that corroborated or challenged it, and (c) the human reviewer who signed off.
- A claim with only (b) is **non-conforming** and must be downgraded or removed.
- A claim with only (c) is **non-conforming** for any technical assertion (human-only is acceptable for *policy* assertions, not for *technical* ones such as "this CVE does not apply").

Evidence artifact. Compliance matrix with three columns per row: `deterministic_ref`, `oracle_ref`, `human_ref`.

Auditor re-check. Sample N rows; for each, confirm all three references resolve to artifacts in L4.

A-05 — Human Reviewer is the Judge of Record

Controls: T-01, T-04, T-05

What. The named human reviewer — not Amp, not the oracle — issues the compliance verdict. This is the documented answer to *"who verifies the verifier."*

Implementation.

- Every artifact entering the FDA submission is signed off by a named human in the run log.
- The reviewer's sign-off must state, per artifact: "I reviewed the diff, the deterministic check outputs, and the oracle findings, and I accept/reject."
- The reviewer may not delegate the **verdict** to Amp. They may delegate *checks* (e.g. "run pytest"), but not the *verdict*.

Evidence artifact. Signed review record (name, role, date, artifact hash, disposition, free-text rationale).

Auditor re-check. Confirm the reviewer's identity, role, and that the artifact hash they signed matches the artifact in L4.

A-06 — Immutable Audit Trail

Controls: T-02, T-03 (forensic), T-05

What. The evidence package (diffs, test outputs, oracle findings, scan JSON, review records) is stored tamper-evidently. Amp's default thread logs are **not** tamper-evident and must not be cited as-is.

Implementation.

- Export the Amp thread (tool calls, diffs, test outputs, oracle findings) to a file.
- Hash-chain the export: `h[i] = SHA256(h[i-1] || content[i])`, with `h[0]` pinned to a trusted value (e.g. a notarized timestamp).
- Store the chain in a WORM store, or sign git commits containing the artifacts with the reviewer's key (`git commit -S`).
- Include the export, the chain, and the signature in the FDA submission.

Evidence artifact. `evidence_package.zip` + `chain.json` + `signature.asc`.

Auditor re-check. Recompute the hash chain from the artifacts; verify the signature; verify `h[0]` against the notarized timestamp.

A-07 — Scanner Configuration is Part of the Evidence

Controls: T-03

What. The *configuration* that produced a scan result is evidence, not just the result. This prevents "narrow the globs to make the CVE disappear."

Implementation.

- For every scan, log: scanner name + version, `scan_types`, `quick_scan` flag, `include_path`, `exclude_path`, `pr_baseline`/`pr_incremental` if used, and the git commit SHA of the tree scanned.
- Any change to scan scope between the run cited in the submission and a prior run must be justified in the run log and approved (A-01).

Evidence artifact. `scan_manifest.json` per scan, referenced from the compliance matrix.

Auditor re-check. Re-run the scanner with the manifest's configuration against the cited git SHA; result must match.

A-08 — Known-Weakness Register for SBOMator

Controls: T-01 (expectation management), T-05

What. SBOMator has documented weaknesses (FDA_SBOM_Assessment_Report.md, Dec 2025): 14–86% CVE miss rate, false positives (CVE-2024-52533 mis-applied to `json-glib-1.0`), 0% license/hash coverage on some projects, VEX contradicting SBOM. These are **not** hidden from the submission; they are stated with the compensating controls.

Implementation.

- The submission includes a "Known limitations of the generation tooling" section listing each weakness and the compensating control (e.g. "SBOMator miss rate compensated by Grype + Trivy cross-scan, see A-02").
- No weakness is compensated by an LLM verdict alone.

Evidence artifact. The known-weakness register, cross-referenced to A-02 evidence.

Auditor re-check. Confirm each listed weakness has a non-LLM compensating control with evidence.

A-09 — Prompt-Injection and Untrusted-Content Boundary

Controls: T-04

What. The agent handles untrusted content (CVE descriptions, upstream package metadata, vendor advisories). Prompt injection in any of these must not elevate the agent's authority.

Implementation.

- Untrusted content is treated as data, not instructions, per standard Amp practice.
- The agent must not change scan scope (A-07), edit artifacts (A-01), or issue a verdict (A-05) in response to content inside an untrusted document.
- Oracle review (A-03) is one compensating check: an injection that successfully steered the actor cannot also steer the oracle through the same document, because the oracle receives the *diff and files*, not the actor's reasoning.

Evidence artifact. Run log confirming no scope/verdict changes occurred without human approval during the run.

Auditor re-check. Sample untrusted inputs (CVE descriptions, advisories) and confirm the agent's actions stayed within A-01.

A-10 — Test-Skip and Suppression Detection (Unit Testing)

Controls: T-06 (primary), T-02, T-05

What. For unit testing, the motivated-grading surface is skipped, disabled, or xfail-marked tests, plus tests written only to inflate coverage without exercising behavior. A deterministic detector is required because LLM review alone cannot reliably catch these.

Implementation.

- A deterministic script (e.g. `pytest --co -q` piped through a skip-detector, or a grep for `@pytest.mark.skip`, `@Ignore`, `@Disabled`, `xfail`) fails the build if any test is skipped or disabled without a linked justification ID.
- Each justification ID must resolve to a row in the test-plan/risk-matrix traceability file (A-04 pattern). Unresolved skips are a non-conformance.
- Oracle (A-03) reviews the diff of *added* tests for coverage-inflation patterns: tests that call a function but assert nothing meaningful, or copy-paste assertions across unrelated tests.
- Coverage delta per test is logged: a test that adds <1% coverage with no assertion is flagged for human review (L3).

Evidence artifact. `skip_audit.json` (list of skipped tests + justification IDs) + oracle review of added tests + coverage-delta log.

Auditor re-check. Re-run the skip detector on the pinned SHA; any unresolved skip fails the check. Re-run coverage with `--cov` and confirm the delta attributed to each new test matches the log.

A-11 — Coverage Scope is Part of the Evidence (Code Coverage)

Controls: T-07 (primary), T-03, T-05

What. For code coverage, the motivated-grading surface is the *scope*, not the percentage: `omit`/`exclude`/`# pragma: no cover`/`// LCOV_EXCL_LINE` patterns can narrow the measurement to hit a threshold. The configuration that produced a coverage number is evidence, not just the number.

Implementation.

- For every coverage run, log: tool + version, the `omit`/`exclude` file list, all `pragma: no cover` / `LCOV_EXCL` markers with file:line, the git SHA, and the safety-class declaration per file from the risk file.
- Any file marked Class B or C in the risk file **must** appear in the coverage scope. Exclusion of a Class B/C file is a non-conformance and requires a documented deviation approved at L3.
- Threshold gates (e.g. 100% branch for Class C per IEC 62304 §5.5.3) are evaluated against the *declared* scope, not the *measured* scope. A pass on a narrowed scope is not a pass.
- Oracle (A-03) reviews the diff of the coverage config for any new `omit`/`exclude`/`pragma: no cover` entries since the last submission.

Evidence artifact. `coverage_manifest.json` (tool, version, scope, excludes, SHA) + raw `.gcda`/`.coverage` + JSON/HTML report + risk-file safety-class mapping.

Auditor re-check. Re-run the coverage tool with the manifest's scope against the cited git SHA; the percentage and the per-file coverage must match the evidence package. Compare the `omit` list against the risk file: every Class B/C file must be in scope.

A-12 — Pen-Test Scope and Tester Identity are Part of the Evidence (Penetration Testing)

Controls: T-08 (primary), T-04, T-05

What. For penetration testing, the dominant risks are scope narrowing by the AI actor (T-04: the AI talks the human tester into a narrow scope) and single-verdict dependence (T-05: the pen test is a single human's report with no cross-check). The architecture's shape changes here: the human pen tester is **both** L0 (actor) and L3 (judge of record). Amp and the oracle are **supporting** tools, not the actor. This is acceptable only because (a) pen testing is a licensed/professional activity with identity attestation, and (b) the oracle provides a cross-vendor adversarial check on the *plan and completeness*, not on the tester's reasoning.

Implementation.

- The test plan must trace to the threat model: every threat ID has a corresponding test activity. Untraced threats are a non-conformance. This is the primary deterministic gate (L1).
- The pen tester's identity and credentials are attested (name, role, employer, certification if applicable, date window). Amp may not be named as the pen tester of record in the submission.
- Amp may run DAST tools (OWASP ZAP, Nuclei, Burp, Nikto) and surface deterministic findings, but the DAST output is **supplementary**, not the pen-test report.
- Oracle (A-03) reviews the test plan for completeness against the threat model and reviews the findings for false-negative bias ("only the automated scanner was run"). Oracle output is required, not optional, because L1 is weak for pen testing.
- Do **not** claim in the submission that Amp "ran the pen test." It ran DAST tools. The pen tester of record is the named human.

Evidence artifact. `pentest_manifest.json` (plan, threat-ID traceability, scope, tester identity) + DAST tool outputs + tester's signed report + oracle completeness review.

Auditor re-check. Verify every threat ID in the risk file has a corresponding test activity in the plan. Verify the tester's identity attestation. Re-run the DAST tools and compare outputs. Confirm the submission does not name Amp as the pen tester.

A-13 — Static-Analysis Suppression and Baseline Integrity (Parasoft C/C++test)

Controls: T-09 (primary), T-03, T-05

What. For static analysis, the motivated-grading surface is **suppression and baseline manipulation** — the cover-up vector. Parasoft's *Static Analysis for FDA Software Compliance* white paper describes context-sensitive suppressions that "prevent rules from firing under specific circumstances" and customizable rule severities — legitimate noise-reduction features that are also the exact mechanisms an AI agent or pressured operator can use to make a release appear compliant without fixing the code. The FDA's Least Burdensome Approach puts quality responsibility on the device maker, and "there are no FDA-certified tools" — so "we ran Parasoft and it passed" is not evidence unless the rule set, scan scope, exclusions, suppressions, baseline, and tool version are independently evidenced.

Why this is a real (not total) mitigation. Parasoft's context-suppression and customizable-severity features are legitimate noise-reduction tools, but they are exactly the mechanisms that make "we ran static analysis and it passed" single-verdict-dependent. A-13 makes the suppression surface itself the evidence, so a cover-up requires falsifying the manifest — which A-06 (immutable trail) and A-03 (oracle diff review) detect.

Implementation.

- Record the exact Parasoft product (C/C++test / C/C++test CT), version, build, and execution environment (host/target, compiler, OS).
- Record rule-pack identity as an immutable configuration hash; record standards profiles enabled (MISRA C/C++, CERT C/C++, AUTOSAR C++14, CWE, OWASP as applicable).
- Record the complete source-scope manifest and all exclusions; any excluded safety-critical source path is a non-conformance requiring a documented L3 deviation.
- Record raw findings, the normalized report, exit status, and timestamps.
- Record baseline identity/hash and the baseline delta (new, resolved, suppressed findings vs. the prior accepted submission/build).
- Record a diff of rule configuration and suppressions since the prior accepted submission/build.
- Every suppression / false-positive disposition is linked to a justification, owner, risk item, affected file:rule, date, and approval. Inline (in-code) suppressions must remain visible in review.
- L3 named-human approval is required for any suppression in safety/risk-control code or for any high-severity finding.
- L2 cross-vendor adversarial review (oracle) of the suppression/configuration diff is required; the oracle is **not** the judge of record.
- Fail-closed: missing, stale, unsigned, or inconsistent static-analysis evidence is a non-conformance. A "zero findings" claim is rejected unless rule set, scan scope, exclusions, suppressions, baseline, and tool version are independently evidenced.
- Hash-chained / immutable retention under L4 (A-06).

Evidence artifact. `static_analysis_manifest.json` (tool, version, env, rule-pack hash, profiles, scope, exclusions, baseline hash, baseline delta, suppression diff) + raw Parasoft report (HTML/PDF/XML) + suppression register (justification/owner/risk/file:rule/date/approval) + oracle review of the suppression diff.

Auditor re-check. Re-run Parasoft C/C++test with the manifest's rule-pack and scope against the cited git SHA; findings and exit status must match. Recompute the baseline delta. Verify every suppression resolves to a signed justification and that no safety-class file is excluded. Confirm "zero findings" claims include the full evidence shape, not just the count.

5. Control → Threat Coverage Matrix (A-01..A-13, T-01..T-09)

T-01..T-05 are the original Anthropic-derived threats (Section 2). T-06..T-08 are the process-specific threats added for unit testing, code coverage, and penetration testing. T-09 is the static-analysis suppression/cover-up threat added for A-13 (see §9.4 and Appendix B).

	A-01	A-02	A-03	A-04	A-05	A-06	A-07	A-08	A-09	A-10	A-11	A-12	A-13
T-01 motivated grading		X	X	X	X			X					
T-02 covert sabotage	X					X				X			
T-03 cover-up via scope	X					X	X				X		X
T-04 recruit human / inj			X		X				X			X	
T-05 single-verdict		X		X	X	X		X		X	X	X	X
T-06 test-skip / inflate		X	X		X					X			
T-07 coverage-scope nar.	X		X		X	X	X				X		
T-08 pen-test scope/plan			X	X	X	X						X	
T-09 static-anal. supp.	X		X	X	X	X	X						X

X = primary or compensating control. Every threat has ≥**2** controls; T-01, T-05, T-07, T-08, T-09 have ≥**4**. No threat relies on a single control. T-06..T-08 are added by Section 9 and apply to unit testing, code coverage, and pen testing; T-09 applies to static analysis (A-13).

6. End-to-End Run Procedure (what the auditor watches)

For one FDA submission artifact — e.g. a VEX "not affected" status for CVE-X on component Y:

1. **L0 — Generate.** SBOMator produces `sbom.json` + `vex.json` at a pinned git SHA. Agent records the SHA and scan manifest (A-07).
2. **L1 — Deterministic check.** CycloneDX schema validation; Grype + Trivy on the SBOM; `check_purl_quality.py` for license/hash/supplier coverage; Parasoft on changed C/C++ (A-02). Record outputs.
3. **L2 — Oracle review.** Invoke `oracle` with intent, files, and "file:line blockers only; no boolean" output shape. Record task + response (A-03).
4. **L3 — Human review.** Named reviewer reads the diff, the L1 outputs, and the L2 findings; dispositions each finding; signs off or rejects (A-04, A-05).
5. **L4 — Immutize.** Export the thread; hash-chain; sign git commit containing all artifacts (A-06).
6. **File.** The submission cites the compliance matrix row (A-04) with its three references; the auditor can re-run steps 1–2 from the manifest (A-07) and re-verify step 5 (A-06).

7. What an FDA Auditor Should Be Told, Plainly

*SBOMator uses an AI orchestration tool (Amp) to generate and assemble evidence for this submission. Amp is **not** the judge of record. The judge of record is the named human reviewer whose signature appears on each artifact. AI is used in two roles: (1) to run deterministic scanners and tests, whose outputs are reproducible and not produced by an LLM; and (2) to provide a cross-vendor,*

read-only adversarial review (OpenAI GPT-5.6) of the artifacts, whose output is a list of findings with file:line references, never a pass/fail verdict. We are aware of the July 2026 Anthropic agentic-misalignment findings, in particular that an LLM judge can exhibit motivated grading. Our control set (A-01 through A-09) is constructed so that no single AI verdict is load-bearing for any compliance claim, every technical claim has at least one deterministic check and one human sign-off, and the full evidence package is hash-chained and signed. For process-specific risks (test-skip, coverage-scope narrowing, pen-test scope, static-analysis suppression), controls A-10 through A-13 extend the same invariants. The question "who verifies the verifier" is answered by control A-05: a named human reviewer, using an evidence package whose integrity is guaranteed by A-06.

8. Open Items Before Any Submission

- Implement the hash-chain exporter (A-06) as a small script in `C:\SBOMATOR-1-3-x\tools\`. Today Amp exports threads but does not hash-chain them.
- Wire `mcp__endor_cli_tools__scan` calls to always emit a `scan_manifest.json` (A-07).
- Produce the compliance-matrix template with `deterministic_ref / oracle_ref / human_ref` columns (A-04).
- Add a "Known limitations of the generation tooling" section to the submission template, populated from `FDA_SBOM_Assessment_Report.md` (A-08).
- Decide and document the human reviewer(s) of record per submission (A-05).
- Implement the skip-detector script (A-10) for the unit-testing pipeline.
- Implement the coverage-scope manifest emitter (A-11) that cross-checks the `omit` list against the risk file's safety-class declarations.
- Implement the pen-test manifest template (A-12) with threat-ID traceability and tester-identity attestation fields.
- Implement the static-analysis manifest emitter (A-13) for Parasoft C/C++test: rule-pack hash, standards profiles, source scope/exclusions, baseline hash + delta, suppression diff, and the signed suppression register.
- Run one end-to-end dry run on the client project (an Israeli medical-device startup specializing in image-guided surgical navigation) and verify all 13 controls produce evidence across SBOM, static, unit, coverage, and pen-test processes. The client working tree and branch are held internally and are not named in this document.

9. Process-Specific Control Extensions

The 5-layer architecture (Section 3) and controls A-01..A-09 apply to every FDA-required verification process. Controls A-10..A-13 add the process-specific determinism gates that each new process needs. This section shows how the layers *redistribute* per process, which FDA standard anchors each process, and where the motivated-grading surface lives in each.

9.1 Layer Redistribution per Process

Process	L1 (deterministic) weight	L2 (oracle) focus	New control	Motivated-grading surface
SBOM / VEX	High	VEX justification truthfulness	A-07	Scanner scope narrowing; VEX "not affected" without code-path evidence.
Static Code Analysis	**Very high**	FP dispositions + rule suppressions + baseline shifts	**A-13** (suppression/baseline); A-07 (config)	Rule suppression; inline suppressions; baseline shifting; reclassifying findings as FP; narrowing scan scope to make findings disappear.
Unit Testing	High	Skipped/disabled tests + coverage-inflation tests	**A-10**	`@skip`, `@Ignore`, `xfail`; tests that call but do not assert.
Code Coverage	High	`omit`/`exclude`/`pragma : no cover` scope	**A-11**	Excluding files/functions/branches to hit a threshold. Scope is the surface, not the percentage.
Penetration Testing	**Low**	Test-plan completeness vs. threat model; false-negative bias	**A-12**	Narrowing the test scope; "only the automated scanner was run." T-04 (recruit human) is dominant.

Pattern: the more deterministic the process, the more L1 dominates and the easier the mapping. The less deterministic (pen testing), the more L2 and L3 must compensate, and the more explicit the submission must be that the human is the actor.

9.2 FDA Standard Anchors per Process

Process	FDA / IEC / ISO anchor	What the standard requires
SBOM / VEX	FDA 2023 Premarket Cybersecurity Guidance; 21 CFR 820.30(j); NTIA minimum elements	SBOM per device; VEX for known exploitable vulnerabilities; traceability of components.
Static Code Analysis	IEC 62304 §5.5; ISO 14971 risk control; FDA 2023 cyber guidance §IV.C	Software unit verification; static analysis as risk-control verification; CWE-classified findings.
Unit Testing	IEC 62304 §5.5; 21 CFR 820.30(f) Design Verification; FDA Design Control Guidance	Unit verification per safety class; pass/fail recorded; test plan traced to requirements.
Code Coverage	IEC 62304 §5.5.3 (Class A/B/C); DO-178C analogue (MC/DC for Level A)	Statement / branch / MC-DC coverage per safety class; 100% branch for Class C; coverage of risk-control code.
Penetration Testing	FDA 2023 Premarket Cybersecurity Guidance §IV.C; ISO 14971; 21 CFR 820.30(g) Design Validation	Static *and* dynamic/penetration testing; threat-model-driven; risk-control validation in intended use environment.

9.3 Pen-Test Shape Change (important)

Penetration testing is the one process where the architecture's shape changes materially. For SBOM, static, unit, and coverage, the main Amp agent can be the L0 actor because the primary evidence is deterministic scanner/test output. For pen testing, the human pen tester is **both** L0 (actor) and L3 (judge of record). Amp and the oracle are **supporting** tools: Amp runs DAST tools and assembles the evidence package; the oracle reviews the test plan for

completeness against the threat model. This is acceptable to an FDA auditor only because pen testing is a licensed/professional activity with identity attestation, and the oracle provides a cross-vendor adversarial check on the *plan and completeness*, not on the tester's reasoning. The submission must **not** name Amp as the pen tester of record.

9.4 Static-Analysis Evidence Shape (Parasoft C/C++test)

Static analysis is the process with the highest L1 weight and the highest cover-up risk. Parasoft's *Static Analysis for FDA Software Compliance* white paper describes context-sensitive suppressions that "prevent rules from firing under specific circumstances" and customizable rule severities — legitimate noise-reduction features that are also the exact mechanisms an AI agent or pressured operator can use to make a release appear compliant without fixing the code. The FDA's Least Burdensome Approach puts quality responsibility on the device maker, and "there are no FDA-certified tools" — so "we ran Parasoft and it passed" is not evidence unless the rule set, scan scope, exclusions, suppressions, baseline, and tool version are independently evidenced. Control A-13 makes the suppression surface itself the evidence.

A "zero findings" claim is not sufficient on its own. The evidence package must show that the zero is real, not manufactured by narrowing scope or suppressing rules. The minimum static-analysis evidence shape is:

- **Tool identity:** Parasoft product (C/C++test / C/C++test CT), exact version, build, and execution environment (host/target, compiler, OS).
- **Rule-pack identity:** immutable hash of the rule configuration; standards profiles enabled (MISRA C/C++, CERT C/C++, AUTOSAR C++14, CWE, OWASP as applicable).
- **Source scope:** complete file manifest scanned and all exclusions, with safety-class per file from the risk file.
- **Findings:** raw findings, normalized report, exit status, and timestamps.
- **Baseline:** baseline identity/hash and baseline delta (new, resolved, suppressed vs. the prior accepted submission).
- **Suppression diff:** diff of rule configuration and suppressions since the prior accepted build.
- **Suppression register:** every suppression / false-positive disposition linked to a justification, owner, risk item, affected file:rule, date, and approval.
- **Approvals:** L3 named-human approval for suppressions in safety/risk-control code or high-severity findings; L2 oracle review of the suppression/configuration diff.

Example manifest (schema sketch, not a tool output):

```
{
  "tool": "Parasoft C/C++test", "version": "2025.1",
  "env": "host:gcc11/x86_64; target:cortex-m4",
  "rule_pack_hash": "sha256:...",
  "profiles": ["MISRA-C:2023","CERT-C","AUTOSAR-C++14","CWE"],
  "scope_manifest": "scope.sha256", "exclusions": [],
  "git_sha": "<pinned commit>",
  "findings_raw": "parasoft-report.xml",
  "findings_normalized": "findings.json", "exit_status": 0,
  "baseline_hash": "sha256:...", "baseline_delta": "delta.json",
  "suppression_diff": "supp-diff.patch",
  "suppression_register": "suppress.json"
}
```

9.5 Invariants That Do Not Change Across Processes

- **A-04** (no single-verdict dependence): every compliance claim still needs `deterministic_ref / oracle_ref / human_ref`, in every process.

- **A-05** (human is judge of record): Amp never issues the verdict, in any process. For pen testing, the human is also the actor.
- **A-06** (immutable audit trail): every process's evidence is hash-chained and signed.
- **A-08** (known-weakness register): each tool's known limitations are stated with compensating controls (Parasoft FP rate; coverage tools cannot detect missing tests; DAST blind spots).
- **A-09** (prompt-injection boundary): untrusted content (CVE descriptions, pen-test tool output, advisories) is data, not instructions, in every process.

9.6 Honest Caveats

- Do not claim Amp "ran the pen test." It ran DAST tools. The pen tester of record is the human.
- For coverage, the motivated-grading surface is the *scope*, not the percentage. A 100% branch number on a narrowed scope is meaningless. A-11 is the control that catches this.
- For unit testing, "tests pass" is necessary but not sufficient. IEC 62304 and the FDA reviewer want *test plan adequacy traced to the risk matrix*, which is L3 work, not L1.
- For static analysis, rule suppression and baseline manipulation are the cover-up vector. A-13 makes the suppression surface itself the evidence (suppressions, baseline, and rule-pack identity are hashed and diffed); A-07 handles scanner-scope config. Without A-13, “we ran Parasoft and it passed” is exactly the single-verdict-dependent claim that FDA AI-Enabled Device guidance and NIST AI RMF treat as non-conforming.
- The architecture does not make any of these processes *more rigorous* than they already are. It makes them *auditable*, which is the actual FDA requirement.

10. References

- Anthropic, *Agentic Misalignment (Summer 2026)* — https://alignment.anthropic.com/2026/agentic-misalignment-summer-2026/
- Anthropic, *Agentic Misalignment: How LLMs Could Be Insider Threats* (June 2025) — https://www.anthropic.com/research/agentic-misalignment
- Lynch, A. et al., *Agentic Misalignment: How LLMs Could Be Insider Threats*, arXiv:2510.05179 (Oct 2025) — https://arxiv.org/abs/2510.05179
- Costanza-Chock, S., Raji, I. D., & Buolamwini, J. (2022). *Who Audits the Auditors? Recommendations from a field scan of the algorithmic auditing ecosystem.* In FAccT ’22 (pp. 1571–1583). ACM. — https://doi.org/10.1145/3531146.3533213
- Kim, R. M., Kuehnert, B., Lai, A., Holstein, K., Heidari, H., & Ghani, R. (2026). *Toward Third-Party Assurance of AI Systems: Design Requirements, Prototype, and Early Testing.* arXiv:2601.22424 — https://arxiv.org/abs/2601.22424
- NIST, *Artificial Intelligence Risk Management Framework (AI RMF 1.0)*, NIST AI 100-1 (Jan 2023) — https://doi.org/10.6028/NIST.AI.100-1
- NIST, *AI Risk Management Framework: Generative AI Profile*, NIST AI 600-1 (July 2024) — https://doi.org/10.6028/NIST.AI.600-1
- FDA, *Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations* (Draft Guidance, Jan 2025) — https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing

- FDA, *Premarket Cybersecurity Guidance for Medical Devices* (2023) — https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-content-premarket-submissions
- FDA, *General Principles of Software Validation* (Final Guidance, Jan 2002) — https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation
- Parasoft Corporation, *Static Analysis for FDA Software Compliance* (Technical White Paper) — https://www.parasoft.com/white-paper/static-analysis-for-fda-software-validation-compliance/
- IEC 62304:2006+A1:2015+A2:2020, *Medical device software — Software life cycle processes* (§5.5 Software Unit Verification, §5.5.3 Coverage)
- 21 CFR 820.30, *Design controls* (f) Design Verification, (g) Design Validation, (j) Design Transfer
- ISO 14971:2019, *Application of risk management to medical devices*
- DO-178C, *Software Considerations in Airborne Systems and Equipment Certification* (MC/DC analogue for Level A)
- NTIA, *Minimum Elements for a Software Bill of Materials (SBOM)*
- Internal: `C:\Users\danie\FDA_SBOM_Assessment_Report.md` (SBOMator known weaknesses, Dec 2025)
- Internal: `C:\Users\danie\ESL_Fixinator_Workflow.drawio` (existing workflow diagram)
- Internal: `C:\SBOMATOR-1-3-x` (active SBOMator working tree)
- Internal: client project for dry run — an Israeli medical-device startup specializing in image-guided surgical navigation. The working tree and branch are held internally and are not named in this document.

End of document — Draft v2.1. This control set is an architecture, not a warranty. No part of it should be cited to an FDA reviewer without the corresponding evidence artifacts from L4.